. 2019 Dec 13;9:19024. doi: 10.1038/s41598-019-54204-z

Table 2.

Prediction of clinical decline (24 months) assessed by MMSE scores, according to CSF biomarker status.

Biomarker	Change in score, BM-positive, estimate (95% CI)	Change in score, BM-negative, estimate (95% CI)	Difference between change in score, BM-negative and BM-positive, estimate (95% CI)
pTau/Aβ(1–42)	–2.13 (–2.39 to –1.87)	–2.31 (–2.73 to –1.89)	–0.05 (–0.34 to 0.24)	–0.74 (–1.10 to –0.38)	–2.08 (–2.47 to –1.68)	–1.57 (–2.14 to –1.01)
tTau/Aβ(1–42)	–2.13 (–2.39 to –1.88)	–2.28 (–2.69 to –1.86)	–0.04 (–0.33 to 0.25)	–0.77 (–1.12 to –0.41)	–2.10 (–2.49 to –1.71)	–1.51 (–2.07 to –0.95)
Aβ(1–42)	–1.96 (–2.21 to –1.71)	–1.99 (–2.37 to –1.62)	–0.04 (–0.34 to 0.27)	–0.81 (–1.19 to –0.42)	–1.92 (–2.32 to –1.53)	–1.19 (–1.74 to –0.64)
pTau	–2.23 (–2.53 to –1.94)	–1.99 (–2.49 to –1.49)	–0.43 (–0.69 to –0.18)	–1.16 (–1.48 to –0.84)	–1.80 (–2.20 to –1.40)	–0.83 (–1.44 to –0.22)
tTau	–2.07 (–2.39 to –1.75)	–1.90 (–2.39 to –1.40)	–0.68 (–0.93 to –0.43)	–1.20 (–1.52 to –0.87)	–1.40 (–1.81 to –0.99)	–0.70 (–1.30 to –0.10)

Biomarker

Change in score, BM-positive, estimate (95% CI)

Change in score, BM-negative, estimate (95% CI)

Difference between change in score, BM-negative and BM-positive, estimate (95% CI)

ADNI

BioFINDER

ADNI

BioFINDER

ADNI

BioFINDER

pTau/Aβ(1–42)

–2.13

(–2.39 to –1.87)

–2.31

(–2.73 to –1.89)

–0.05

(–0.34 to 0.24)

–0.74

(–1.10 to –0.38)

–2.08

(–2.47 to –1.68)

–1.57

(–2.14 to –1.01)

tTau/Aβ(1–42)

–2.13

(–2.39 to –1.88)

–2.28

(–2.69 to –1.86)

–0.04

(–0.33 to 0.25)

–0.77

(–1.12 to –0.41)

–2.10

(–2.49 to –1.71)

–1.51

(–2.07 to –0.95)

Aβ(1–42)

–1.96

(–2.21 to –1.71)

–1.99

(–2.37 to –1.62)

–0.04

(–0.34 to 0.27)

–0.81

(–1.19 to –0.42)

–1.92

(–2.32 to –1.53)

–1.19

(–1.74 to –0.64)

pTau

–2.23

(–2.53 to –1.94)

–1.99

(–2.49 to –1.49)

–0.43

(–0.69 to –0.18)

–1.16

(–1.48 to –0.84)

–1.80

(–2.20 to –1.40)

–0.83

(–1.44 to –0.22)

tTau

–2.07

(–2.39 to –1.75)

–1.90

(–2.39 to –1.40)

–0.68

(–0.93 to –0.43)

–1.20

(–1.52 to –0.87)

–1.40

(–1.81 to –0.99)

–0.70

(–1.30 to –0.10)

Based on PET-optimised cut-offs for Aβ(1–42), pTau/Aβ(1–42) and tTau/Aβ(1–42). Analyses shown with adjustment for age, sex, years of education but without adjustment for APOEε4 status. Change in score calculated from baseline to 24 months in the ADNI MCI and BioFINDER MCS populations. MMSE, Mini-Mental State Examination; CSF, cerebrospinal fluid; BM, biomarker; CI, confidence interval; ADNI, Alzheimer’s Disease Neuroimaging Initiative; pTau, phosphorylated Tau; tTau, total Tau; PET, positron emission tomography; MCI, mild cognitive impairment; MCS, mild cognitive symptoms.